Doxorubicin (Conventional) e Cardiomiopatia
Resultado da verificação da interação do medicamento Doxorubicin (Conventional) com doença Cardiomiopatia quanto a segurança no uso em conjunto.
Na verificação da interação, conforme informações das fontes confiáveis como Drugs.com, Rxlist.com, Webmd.com, Medscape.com, foram identificadas as contra-indicações ou efeitos colaterais que podem prejudicar a saúde ou aumentar efeito negativo ao consumir o medicamento com esta doença concomitante.
Consumidor:Dano miocárdico, incluindo aguda a insuficiência ventricular esquerda pode ocorrer com a doxorrubicina. O risco de cardiomiopatia é proporcional à exposição cumulativa com taxas de incidência de 1% a 20% para o acumulado de doses variando de 300 mg/m2 a 500 mg/m2 quando a doxorrubicina é administrado a cada 3 semanas. O risco de cardiomiopatia é ainda maior, com concomitante cardiotoxic terapia. Além disso, a doxorrubicina pode também causar arritmias, inclusive com risco de vida eventos em qualquer ponto durante o tratamento. Avaliar FEVE antes e regularmente durante e após o tratamento com doxorrubicina. A doxorrubicina é contra-indicado em pacientes com grave insuficiência miocárdica e recente de infarto do miocárdio (últimos 6 meses).
- Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC "Early anthracycline cardiotoxicity." Am J Med 65 (1978): 823-32
- Sperber AD, Cantor AA, Biran H, Keynan A "Selective right ventricular dysfunction following doxorubicin therapy." Isr J Med Sci 23 (1987): 896-9
- Krivit W "Adriamycin cardiotoxicity amelioration by alpha-tocopherol." Am J Pediatr Hematol Oncol 1 (1979): 151-3
- Carter SK "Adriamycin-a review." J Natl Cancer Inst 55 (1975): 1265-74
- Billingham ME, Bristow MR, Glatstein E, Mason JW, Masek MA, Daniels JR "Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation." Am J Surg Pathol 1 (1977): 17-23
- Freter CE, Lee TC, Billingham ME, Chak L, Bristow MR "Doxorubicin cardiac toxicity manifesting seven years after treatment. Case report and review." Am J Med 80 (1986): 483-5
- Lum BL, Svec JM, Torti FM "Doxorubicin: alteration of dose scheduling as a means of reducing cardiotoxicity." Drug Intell Clin Pharm 19 (1985): 259-64
- Porembka DT, Lowder JN, Orlowski JP, Bastulli J, Lockrem J "Etiology and management of doxorubicin cardiotoxicity." Crit Care Med 17 (1989): 569-72
- Fu LX, Waagstein F, Hjalmarson A "A new insight into adriamycin-induced cardiotoxicity." Int J Cardiol 29 (1990): 15-20
- Barendswaard EC, Prpic H, Van der Wall EE, Camps JA, Keizer HJ, Pauwels EK "Right ventricle wall motion abnormalities in patients treated with chemotherapy." Clin Nucl Med 16 (1991): 513-6
- Steinherz L, Steinherz P "Delayed cardiac toxicity from anthracycline therapy." Pediatrician 18 (1991): 49-52
- Speyer JL, Green MD, Dubin N, Blum RH, Wernz JC, Roses D, Sanger J, Muggia FM "Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast." Am J Med 78 (1985): 555-63
- Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA "A clinicopathologic analysis of adriamycin cardiotoxicity." Cancer 32 (1973): 302-14
- Mortensen SA, Olsen HS, Baandrup U "Chronic anthracycline cardiotoxicity: haemodynamic and histopathological manifestations suggesting a restrictive endomyocardial disease." Br Heart J 55 (1986): 274-82
- Lee BH, Goodenday LS, Muswick GJ, Yasnoff WA, Leighton RF, Skeel RT "Alterations in left ventricular diastolic function with doxorubicin therapy." J Am Coll Cardiol 9 (1987): 184-8
- Shapira J, Gotfried M, Lishner M, Ravid M "Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation." Cancer 65 (1990): 870-3
- Devoy MA, Tomson CR "Fatal cardiac failure after a single dose of doxorubicin in myeloma- associated cardiac amyloid." Postgrad Med J 68 (1992): 69
- Haq MM, Legha SS, Choksi J, Hortobagyi GN, Benjamin RS, Ewer M, Ali M "Doxorubicin-induced congestive heart failure in adults." Cancer 56 (1985): 1361-5
- Benjamin RS, Wiernik PH, Bachur NR "Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule." Cancer 33 (1974): 19-27
- Caviale P, McClellan EL "Adriamycin toxicity. Effects in subsequent anesthesia and surgery." J Kans Med Soc 82 (1981): 553,574
- Lahtinen R, Kuikka J, Nousiainen T, Uusitupa M, Lansimies E "Cardiotoxicity of epirubicin and doxorubicin: a double-blind randomized study." Eur J Haematol 46 (1991): 301-5
- Rinehart JJ, Lewis RP, Balcerzak SP "Adriamycin cardiotoxicity in man." Ann Intern Med 81 (1974): 475-8
- McQuillan PJ, Morgan BA, Ramwell J "Adriamycin cardiomyopathy. Fatal outcome of general anaesthesia in a child with adriamycin cardiomyopathy." Anaesthesia 43 (1988): 301-4
Nome genérico: doxorubicin
Marca comercial: Adriamycin, Adriamycin RDF, Rubex, Adriamycin PFS
Sinônimos: Doxorubicin, DOXOrubicin (Conventional)